<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02290366</url>
  </required_header>
  <id_info>
    <org_study_id>PRO14020322</org_study_id>
    <nct_id>NCT02290366</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation of Focal Brachytherapy Using Cesium-131 For Patients With Low Risk Prostate Cancer</brief_title>
  <official_title>Prospective Evaluation of Focal Brachytherapy Using Cesium-131 For Patients With Low Risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ronald M. Benoit, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The standard options for men with very low risk prostate cancer include active surveillance
      and the standard treatment options for low risk disease, i.e. radical prostatectomy, external
      beam radiotherapy, and whole gland prostate brachytherapy. The present study seeks to
      evaluate focal brachytherapy using the isotope Cesium 131 to treat patients with low risk
      prostate cancer. The goals of the study are to determine the biochemical disease free
      survival at five years in these patients, as well as to determine the acute and late urinary,
      bowel, and sexual toxicity associated with focal prostate brachytherapy using Cesium 131.
      Patients eligible for the study will be men with histologically confirmed adenocarcinoma of
      the prostate with clinical stage T1c-T2aN0M0, Gleason score ≤3+3=6, prostate specific
      antigen(PSA) &lt;10 ng/ml or a PSA density ≤ 0.15 ng/cc, and ≤ 2 cores positive out of a minimum
      of 12 cores sampled. Additionally, patients must have a single, dominant index lesion on MRI.
      The study is a phase II study. Patients will be followed prospectively. Dosimetry will be
      evaluated post-procedure, and PSAs will be obtained every three months in year one and every
      six months from year two through year five. Urinary, bowel, and sexual morbidity will be
      assessed by patient survey prior to treatment , two weeks, after treatment, at three month
      intervals in year one and at six month intervals in years two through five.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Brachytherapy, using Cesium 131</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>biochemical disease free survival</measure>
    <time_frame>five years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Focal Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Focal prostate brachytherapy with Cesium-131</intervention_name>
    <arm_group_label>Focal Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the prostate

          -  Clinical stage T1c-T2aN0M0

          -  Gleason score &lt;= 3+3=6

          -  prostate specific antigen (PSA) &lt;10 ng/ml

          -  &lt;= 2 cores positive out of a minimum of 12 cores sampled
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dawn McBride</last_name>
    <phone>412-623-2764</phone>
    <email>mcbridedl@upmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UPMC Mercy</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald Benoit, MD</last_name>
      <phone>412-232-9012</phone>
    </contact>
    <investigator>
      <last_name>Ronald Benoit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 5, 2014</study_first_submitted>
  <study_first_submitted_qc>November 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2014</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Ronald M. Benoit, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

